Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy

American Journal of Hematology

Volumn 91, Issue 2, 2016, Pages 193-198

  Tavitian, Suzanne ^a,b   Denis, Amélia ^c,d   Vergez, François ^c,e   Berard, Emilie ^a,f   Sarry, Audrey ^a   Huynh, Anne ^a   Delabesse, Eric ^b,c,e   Luquet, Isabelle ^e   Huguet, Françoise ^a   Récher, Christian ^a,b,c   Bertoli, Sarah ^a,b,c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c CANCER RESEARCH CENTER OF TOULOUSE   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e Institut Universitaire du Cancer de Toulouse Oncopole   (France)

^f Faculté de Médecine Centre Hospitalo universitaire   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; BODY MASS; BODY SURFACE; COMPLICATION; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; OBESITY; RETROSPECTIVE STUDY; RISK; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; BODY SURFACE AREA; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; RETROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME;

EID: 84956599895     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24228     Document Type: Article

References (29)

1. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766-781.
2. Ligibel JA, Alfano CM, Courneya KS, et al. American Society of Clinical Oncology position statement on obesity and cancer. J Clin Oncol 2014;32:3568-3574.
3. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638.
4. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010;363:2211-2219.
5. Lyman GH, Sparreboom A. Chemotherapy dosing in overweight and obese patients with cancer. Nat Rev Clin Oncol 2013;10:451-459.
6. Wenzell CM, Gallagher EM, Earl M, et al. Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight. Am J Hematol 2013;88:906-909.
7. Brunner AM, Sadrzadeh H, Feng Y, et al. Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol 2013;88:642-646.
8. Medeiros BC, Othus M, Estey EH, et al. Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Haematologica 2012;97:1401-1404.
9. Lee HJ, Licht AS, Hyland AJ, et al. Is obesity a prognostic factor for acute myeloid leukemia outcome? Ann Hematol 2012;91:359-365.
10. Lin A, Othus M, McQuary A, et al. Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Leuk Lymphoma 2013;54:541-546.
11. Kempf E, Hirsch P, Labopin M, et al. Prognosis of body mass index and chemotherapy dose capping in acute myeloid leukaemia. Leuk Res 2014;38:1425-1429.
12. Castillo JJ, Mulkey F, Geyer S, et al. Obesity is an adverse prognostic factor for overall and disease-free survival in adult acute promyelocytic leukemia but not in acute myeloid leukemia: A pooled analysis from four alliance prospective studies. Blood (ASH Annual Meeting Abstracts) 2013;122:21.
13. Heiblig M, Elhamri M, Nicolini FE, et al. Effect of initial body mass index on survival outcome of patients with acute leukemia: A single-center retrospective study. Clin Lymphoma Myeloma Leuk 2015;15:S7-S13.
14. Crysandt M, Kramer M, Ehninger G, et al. A high BMI is a risk factor in younger patients with de novo acute myelogenous leukemia. Eur J Haematol 2015. [Epub ahead of print]
15. Butturini AM, Dorey FJ, Lange BJ, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol 2007;25:2063-2069.
16. Orgel E, Sposto R, Malvar J, et al. Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group. J Clin Oncol 2014;32:1331-1337.
17. Inaba H, Surprise HC, Pounds S, et al. Effect of body mass index on the outcome of children with acute myeloid leukemia. Cancer 2012;118:5989-5996.
18. Peric KM, Reeves DJ. Tolerability of induction chemotherapy dosing practices in acute myeloid leukemia patients. Leuk Res 2015;39:173-176.
19. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-474.
20. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354-365.
21. LaRochelle O, Bertoli S, Vergez F, et al. Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget 2011;2:850-861.
22. Charlson ME. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-1251.
23. Jourdan E, Boiron JM, Dastugue N, et al. Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: An intent-to-treat long-term analysis of the BGMT experience. J Clin Oncol 2005;23:7676-7684.
24. Jourdan E, Boissel N, Chevret S, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 2013;121:2213-2223.
25. Récher C, Béné MC, Lioure B, et al. Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia. Leukemia 2014;28:440-443.
26. Pigneux A, Harousseau JL, Witz F, et al. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: A report from the GOELAMS. J Clin Oncol 2010;28:3028-3034.
27. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-1918.
28. Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012;30:1553-1561.
29. Beumer JH, Chu E, Salamone SJ. Body-surface area-based chemotherapy dosing: Appropriate in the 21st century? J Clin Oncol 2012;30:3896-3897.